DESCRIPTION

Iconic is a development-stage company, incorporated in December 2002 and currently based in Atlanta, Georgia. The Company is focused on the development and commercialization of novel immunoconjugate proteins called “I-cons™”.The Company’s first prototype, I-con1™, uniquely targets pathological blood vessels (PBV). Iconic has negotiated an exclusive, worldwide license with Yale University with respect to I-con1™ and the I-con™ technology.

MISSION

Iconic is developing proprietary I-cons™, proteins that trigger the immune system to target and destroy unwanted cells in the body. In particular, the Company is investigating the therapeutic use of I-con1™ protein,which has the potential to provide effective therapy for the “wet” form of adult macular degeneration and for many cancers, with the prospect of being useful in treating other diseases as well.

The Company | Technology | Plans for Clinical Studies | Publications | Contact